
Managing Director for Global Health & Development Policy @coeff_giving ; former @the_idb @CGDev @BrookingsInst @usaid. Personal views.
Washington, DC
Joined November 2010
- Tweets81.1K
- Following19.7K
- Followers26.5K
- Likes51.4K
Amanda Glassman retweeted
Announcement of a mining industry-led movement to end TB @ 40th @StopTB Board Meeting on 6 Nov. Mining companies from South Africa and Indonesia launched the Bali Statement on TB and Silicosis and announced a mining industry-led movement to end TB.
#EndTB #Mining #BaliStatement
Amanda Glassman retweeted
Replying to @MssZeeUsman @christiangeraud
They still need help both financial and strategic to address epidemics, and some immediate challenges that are direct consequences of extreme poverty and cannot wait until the new (and essential) econ partnerships materialise.
It’s not necessarily one or the other.
Amanda Glassman retweeted
International Debt Report (World Bank). Interesting analysis of relationship between external debt burden and healthy diet unaffordability over last ten years (pages 71-79). Evidence of debt negatively impacting affordability in pandemic and aftermath. openknowledge.worldbank.org/…
Amanda Glassman retweeted
Kenya / striking table from latest World Bank Economic Update with survey evidence of corruption incidence and impacts at firm level. Note the pronounce U-shape; level of payments to "get things done" is higher but also has peak for mid-size firms. documents.worldbank.org/en/p…
Amanda Glassman retweeted
Today there's a special outstanding @ScienceMagazine issue on GLP-1 drugs, obesity and adipose tissue
science.org/doi/10.1126/scie…
A thread below to summarize some of the papers
Amanda Glassman retweeted
🧬 We’re hiring at the NVIDIA × Lilly AI lab—across both companies!
Help build the next generation of drug discovery, bringing AI, robotics and experimental science together in our joint Bay Area lab.
#Hiring #AIforScience #DrugDiscovery
Amanda Glassman retweeted
Fantastic news. Congratulations to everyone who made this happen!
This is a major step to fully securing the nucleic acid supply chain.
The policy only covers federally funded research. Congress can extend screening to everyone else by passing the Biosecurity Modernization and Innovation Act.
Today, we released the National Policy for Nucleic Acid Synthesis Screening to protect American biotechnology innovation while reducing the risk of misuse.
This policy establishes a new, government-wide screening requirements for synthetic DNA and the equipment used to make it. It will ensure companies selling nucleic acid sequences and synthesis equipment know their customers and prevent the malicious use of these materials and tools.
This policy strengthens our Nation’s biosecurity posture by establishing rigorous U.S. government-wide procurement screening and physical security standards for synthetic biology. It replaces outdated “self-attestation” systems with robust, independent verification. It creates a dynamic, SI-powered screening layer that assesses the biological risk from nucleic acid sequences, allowing the U.S. to anticipate and prevent malicious use and help stop dangerous gain-of-function research.
@NIST will issue rigorous new screening standards and @HHSGov and @USDA will certify synthetic biology providers. Together, these measures will strengthen American biosecurity, safeguard responsible innovation, and establish a global standard for safe and transparent synthetic biology tools and research.
Amanda Glassman retweeted
World Bank / International Debt Report: "IDA-eligible countries paid an average of 8.2% on new private-creditor commitments in 2025—the highest rate since 1989—and 9.4% on new bonds. The gap between the rates IDA-eligible countries paid to official & private creditors ..."
Amanda Glassman retweeted
We’re thrilled @bajeti_hub is featured in Think Tanks to Watch 2026 by @onthinktanks! 🎉 💫
This will help us to share more about our work in PFM, budget transparency & civic engagement in Kenya. 🇰🇪
Explore the featured think tanks: 👇onthinktanks.org/thinktankst…
#ThinkTanksToWatch
Amanda Glassman retweeted
My new NBER WP is up! nber.org/papers/w35975
👉The Global Office: How Globalisation's Frontier is Shifting from Factories to Offices.
1⃣ Portrait of the Global Office side by side with the Global Factory.
2⃣ Five stylised facts:
1) The Office is larger in world GDP but smaller in world trade. Intermediate services exports have grown faster since 2008.
2) All export-linked net job creation since 2008 has been in digitally delivered services (DDS), not manufacturing. Trade-linked DDS jobs pay more.
3) The Global Office is star-shaped with the US as the star; the Global Factory is bloc-shaped, dominated by China.
4) DDSx exports are less sensitive to distance but more sensitive to time zones.
5) Export-led development is shifting to the Office.
Amanda Glassman retweeted
“We can actually get control of these three diseases,” says Mark Dybul, who will return to the Global Fund to Fight AIDS, Tuberculosis, and Malaria after 9 years. scim.ag/4ztROgb
🆕 What makes supply chains resilient? Evidence from India's COVID-19 lockdowns
Today on VoxDev, Gaurav Khanna (@UCSanDiego), Nicolas Morales (@RichmondFed) & @nityanayar (@UTAustinEcon) outline research on supplier exposure to COVID-19 lockdowns: voxdev.org/topic/macroeconom…
Amanda Glassman retweeted
Introducing Learn, a free, personalized medical education platform from OpenEvidence, built to support trainees and clinicians across their entire careers.
As AI changes how doctors work, it matters just as much that it strengthens how they learn.
Clinicians have made OpenEvidence an everyday tool at the point of care. Now we apply that same technology and those same principles to how doctors learn medicine. Developed with leading medical institutions, certifiers, and educators, Learn brings together a suite of tools built on OpenEvidence so every trainee and clinician gets a tailored, evidence-based learning experience.
Amanda Glassman retweeted
Which vaccines do children around the world receive?
Every year, the World Health Organization (WHO) and UNICEF estimate what share of children in each country get each routine vaccine. Their Estimates of National Immunization Coverage cover vaccines against 13 diseases, from measles to rotavirus, in 195 countries since 1980.
They start from the doses that health services report and check them against household surveys. For the small share of countries that haven’t reported any data for the most recent year, WHO and UNICEF estimate coverage from the years before.
The chart shown here is about the vaccine against human papillomavirus (HPV), which causes nearly all cervical cancers. It shows the share of girls who had their last dose between the ages of 9 and 14, measured when they turn 15. Coverage varies a lot from country to country, even within the same world region.
We recently updated our charts with the July 2026 release, which adds 2025 estimates for every country. For HPV, we now have data for 160 countries and territories in 2025, compared with 146 a year earlier.
(This data update was led by Tuna Acisu.)
Amanda Glassman retweeted
Morphine is among the cheapest essential medicines there is. Ten days of oral morphine costs about the same as a loaf of bread.
Yet, in most of the world: the need for severe pain relief still goes unmet.
@morganfairlessb in @indevmag: indevelopmentmag.substack.co…
An 80-Cent Plastic Pouch Is Saving Thousands of Women From Dying in Childbirth nytimes.com/2026/11/03/healt… via @NYTimes
India saw about 496 million people lifted out of poverty between 2011 and 2023 in one of the world’s fastest declines in this metric, the World Bank said, although the gains remain uneven. bloomberg.com/news/articles/…
Global Fund Board Approves New Financing Mechanism to Accelerate Progress Against Malaria and Marks Leadership Transition theglobalfund.org/en/news/20…
GiveWell aims to direct $2.5B+ in new malaria funding from 2027–2032. Malaria still kills around 600k people each year.
We’re exploring many strategies, including the Malaria Impact Accelerator, a proposed partnership with @GlobalFund. Learn more: bit.ly/4yNkD60
























